Guideline for the diagnosis and management of hypertension in adults — 2016

Rodgers, Anthony; Chow, Clara K; Jackson, Rodney T; Patel, Anushka; Usherwood, Tim

doi:10.5694/mja16.01057

Topics

Cardiovascular diseases

Pharmaceutical preparations

To the Editor:

1 The George Institute for Global Health, Sydney, NSW
2 University of Sydney, Sydney, NSW
3 Westmead Hospital, Sydney, NSW
4 University of Auckland, Auckland, NZ

Correspondence: arodgers@georgeinstitute.org

Acknowledgements:

We thank John Chalmers, Bruce Neal and Emily Atkins of The George Institute for Global Health for their assistance in preparing this letter.

Competing interests:

George Health Enterprises, the social enterprise arm of The George Institute for Global Health, has received investment to develop aspirin–statin–BP combinations.

1. Gabb GM, Mangoni AA, Anderson CS, et al. Guideline for the diagnosis and management of hypertension in adults – 2016. Med J Aust 2016; 205: 85-89. <MJA full text>
2. National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. Melbourne: National Stroke Foundation, 2012.
3. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387: 957-967.
4. Xie X, Atkins E, Lv J, Rodgers A. Intensive blood pressure lowering–Authors' reply. Lancet. 2016; 387: 2291.
5. Mancia G, Sega R, Bravi C, De Vito G, et al. Ambulatory blood pressure normality: results from the PAMELA study. J Hypertens 1995; 13: 1377-1390.
6. Lovibond K, Jowett S, Barton P, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet 2011; 378: 1219-1230.
7. National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults 2016. Melbourne: NHF, 2016.
8. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
9. Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular disease events, and blood pressure-and lipid-lowering therapy in Australia. Med J Aust 2016; 204: 320. <MJA full text>

Online responses are no longer available. Please refer to our instructions for authors page for more information.